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Abstract
Background: The growing number of people with dementia, and the increasing cost of care,
provides a major incentive to develop and test methods of supporting them in the community for
longer. Most attention has been given to pharmacological interventions, but there is increasing
recognition that psychosocial interventions may be equally effective, even preferable where
medication has negative side-effects. Reminiscence groups, run by professionals and volunteers,
which use photographs, recordings and other objects to trigger personal memories are probably
the most popular therapeutic approach to working with people with dementia, but there is little
evidence for their effectiveness and cost-effectiveness. The recent inclusion of family carers in
groups with people with dementia, notably in our own pilot studies, has generated informal
evidence that this joint approach improves relationships between people with dementia and their
carers, and benefits both.
Design and methods: This multi-centre, pragmatic randomised controlled trial (RCT) to assess
the effectiveness and cost-effectiveness of joint reminiscence groups for people with dementia and
their family care-givers has two parallel arms – an intervention group and a control group who
receive care as usual. The intervention consists of joint reminiscence groups held weekly for twelve
consecutive weeks, followed by monthly maintenance sessions for a further seven months.
The primary outcome measures are the quality of life of people with dementia, as assessed by QoL-
AD, and their care-givers' mental health as assessed by the GHQ-28. Secondary outcomes include:
the autobiographical memories of people with dementia; the quality of the relationship between
Published: 30 July 2009
Trials 2009, 10:64 doi:10.1186/1745-6215-10-64
Received: 16 June 2009
Accepted: 30 July 2009
This article is available from: http://www.trialsjournal.com/content/10/1/64
© 2009 Woods et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Trials 2009, 10:64 http://www.trialsjournal.com/content/10/1/64
Page 2 of 10
(page number not for citation purposes)
them and their care-givers; and the levels of depression and anxiety felt by them and their care-
giver. Using a 5% significance level, comparison of 200 pairs attending joint reminiscence groups
with 200 pairs receiving usual treatment will yield 80% power to detect a standardised difference
of 0.38 in the QoL-AD rated by the person with dementia and 0.28 in the GHQ-28 or carer-rated
QoL-AD. The trial will include a cost-effectiveness analysis from a public sector perspective.
Discussion: Our Cochrane review (2005) on reminiscence therapy for people with dementia did
not identify any rigorous trials or economic analyses in this field.
Trial Registration: ISRCTN42430123
Background
The development and evaluation of therapeutic interven-
tions intended to benefit people with dementia and their
family carers is the subject of much research interest at
present. In view of the large and growing numbers of peo-
ple with dementia, and the costs associated with meeting
needs for care, there are clear advantages for health and
social care services in supporting people with dementia in
the community for longer but less intensively. However
there is consensus that this should not be at the cost of
additional burden on family carers [1].
Most attention has been given to pharmacological inter-
ventions, but there is increasing recognition that psycho-
social interventions may have comparable value [2,3],
and may be preferable in some contexts, e.g. where medi-
cation may be ineffective or have negative side-effects
[3,4]. A number of systematic reviews of psychosocial
interventions are now available [e.g. [1,5,6], as well as a
number of Cochrane reviews of specific approaches [e.g.
[7,8].
In the UK, Reminiscence Therapy appears to be the most
well-known therapeutic approach to working with people
with dementia. For example, over half of care homes in
Wales claim to offer this approach to their residents [9].
Reminiscence work with people with dementia has an
extensive history [10,11], engendering enjoyable activities
that promote communication and well-being. One factor
in its popularity is that it works with early memories,
which are often intact for people with dementia, thus
drawing on the person's preserved abilities, rather than
emphasising the person's impairments. However, its pop-
ularity has not led to a corresponding body of evidence on
its effects. The existing research literature has been
brought together in our revised Cochrane review on rem-
iniscence therapy for people with dementia [12]. Only
four randomised controlled trials (RCTs) suitable for
analysis were identified. Each examined different types of
reminiscence work; all were small or of poor quality. The
trials together identified significant improvements in cog-
nition and mood 4–6 weeks after treatment, and stress in
care-givers who participated with the person with demen-
tia in a reminiscence group. However, the review con-
cluded that 'in view of the limitations of the studies
reviewed, there is an urgent need for more quality research
in the field'. This dearth of evidence is reflected in the
National Institute for Health and Clinical Excellence and
Social Care Institute for Excellence (NICE-SCIE) Guide-
line on the management and treatment of dementia [3],
which found insufficient evidence to recommend that
reminiscence should be routinely offered to people with
dementia, although its potential impact on mood of the
person with dementia was highlighted.
To take research forward, there is a need to specify clearly
the exact nature of the reminiscence work to be under-
taken and its aims. Typically, a group approach has been
implemented, with 'memory triggers' (photographs,
recordings, artefacts etc.) used to promote personal and
shared memories. A recent development has been to
include family carers in reminiscence groups alongside
their relatives with dementia. Descriptive evaluations sug-
gest that this joint approach (described as 'Remembering
Yesterday Caring Today' – RYCT [13]) may improve the
relationship between carer and person with dementia,
benefiting both [14]. As it is the breakdown of this care-
giving relationship that increases the likelihood of the
person with dementia being placed in an alternative care
setting, such as a care home, this effect could have far-
reaching implications for families, society and public
spending. Our group have reported a very small pilot
study evaluating this joint reminiscence approach (7
patient-carer pairs in the treatment group; 4 in the wait-
ing-list control group), which showed some trends in
improved quality of life for patients and reduced stress for
care-givers [15]. In a larger trial platform, funded by the
Medical Research Council (MRC), improvements in auto-
biographical memory and carer depression were associ-
ated with reminiscence groups containing 50 patient-carer
pairs.
The justification for evaluating the joint reminiscence
approach specifically comes from this promising pilot
data and the great interest in this approach in the field of
reminiscence work [10]. More generally, a recent meta-Trials 2009, 10:64 http://www.trialsjournal.com/content/10/1/64
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analysis [1] on interventions with family carers of people
with dementia suggested that joint approaches may be
more effective in improving carer outcomes than
approaches targeted only at the carer. The previous tradi-
tion in dementia care of interventions for people with
dementia and their carers separate from each other is
being questioned. For example, in many areas of the UK,
Alzheimer Café sessions have been established, with an
agenda including education as well as social contact,
attended by both people with dementia and their carers
[16]. The emphasis has shifted from 'person-centred care'
to 'relationship-centred care', with recognition of the cen-
tral importance of the relationship between person with
dementia and carer to the benefit of both [16]. Although
a joint focus on people with dementia and their care-giv-
ers is not possible for all people with dementia, only 6%
of them have no identifiable care-giver [17], and thus a
higher chance of entering care homes.
The objective of this paper is to describe the study proto-
col of this pragmatic RCT among people with mild to
moderate dementia and their family caregivers. The main
research questions concern whether reminiscence groups
with participants and carers followed by reminiscence-
based maintenance are more (cost)-effective in ameliorat-
ing the quality of life of people with dementia and the
stress on their carers than 'usual treatment'.
Design and methods
Design
The design is a pragmatic eight-centre randomised trial
(Figure 1). After selection, and baseline assessment, pairs
of people with dementia and their family carer are ran-
domised to one of two groups; the intervention group
receives usual care plus joint reminiscence groups and
reminiscence-based maintenance, the control group
receives usual care only. Participants are free to seek addi-
tional assistance and support elsewhere at any time after
baseline. Participants are allowed to enter the study only
after giving signed informed consent in accordance with
the provisions of the Mental Capacity Act 2005 [18]. Gen-
eral ethical approval was obtained through the Multi-cen-
tre Research Ethics Committee for Wales (ref no. 07/
MRE09/58). The study is registered as a clinical trial with
ISRCTN 42430123.
Participants
Recruitment to this trial is taking place through mental
health services for older people in each area (especially
Memory Clinics, Community Mental Health Teams for
Older People and associated professionals including psy-
chiatrists, occupational therapists and Admiral Nurses),
associated day services and through relevant local volun-
tary sector agencies such as the Alzheimer's Society and
Age Concern. Recruitment will be in three waves, giving
centres the opportunity to focus on different geographical
areas in different waves. The Appendix sets out the inclu-
sion and exclusion criteria for participants in the trial.
Randomisation
Local researchers, who do not take part in follow-up
assessments, contact the remote randomisation service of
the North Wales Organisation for Randomised Trials in
Health (NWORTH) when they have up to 24 pairs ready
for randomisation. NWORTH is accredited as a Clinical
Trials Unit by the UK Clinical Research Collaboration
(UKCRC) and funded by the Clinical Research Collabora-
tion Cymru, notably for HTA trials. The same researcher
arranges for the 12 pairs randomised to the intervention
group to attend sessions, and liaises with the group facili-
tator.
Blinding
Though participants cannot be blinded to their allocated
treatment, all follow-up data are gathered by blinded
interviewers. However our experience in the trial plat-
form, shared by similar projects, is that participants may
occasionally and inadvertently inform researchers of the
treatment they are receiving. We aim to reduce this effect
by explicit reminders to participants before the assess-
ment visit and by the use of self-report measures wherever
feasible. We also ask all assessors to record their impres-
sion of the arm to which each participant belongs, and
their confidence in that prediction. This will enable us to
test whether inadvertent loss of blinding leads to bias, and
to adjust for any bias detected.
Intervention
The practice of using joint reminiscence groups attended
by people with dementia and their carers [13] emphasises
active, as well as passive, forms of reminiscence by both
carers and the people with dementia. Pairs attend 12 two-
hour sessions, where possible in a social not clinical set-
ting. Each session focuses on a different theme, including
childhood, schooldays, working life, marriage, and holi-
days and journeys. Couples are encouraged to contribute
with materials brought from home. Each session blends
work in large and small groups, and a range of activities
including art, cooking, physical re-enactment of memo-
ries, singing and oral reminiscence. The inclusion of the
person with dementia is paramount. In the joint reminis-
cence groups facilitators and volunteers guide carers to
allow the person with dementia to respond and to value
their contribution.
There is a limit of 12 pairs for the two trained facilitators
in each group, supported by several trained volunteers.
Our previous experience suggested that ideally these vol-Trials 2009, 10:64 http://www.trialsjournal.com/content/10/1/64
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Flow diagram for the trial Figure 1
Flow diagram for the trial.
Screened by inclusion criteria: 
Diagnosis of mild to moderate dementia; 
Person with dementia has informant (for measures); 
Community dwelling; 
Absence of severe agitation, severe hearing difficulties, severe physical problems;  
Family caregiver able and willing to participate in joint reminiscence groups. 
Informed consent taken from person with dementia and their carer
Control group (N = 288): 
x Usual  care 
Intervention group (N = 288): 
x  Usual care, and  
x  RYCT joint reminiscence group sessions 
for the person with dementia and their 
carer; weekly meetings for 12 weeks 
First follow-up - 3 months after baseline 
Repeat outcome measures completed by person with dementia and their carer 
x  RYCT maintenance sessions for the 
person with dementia and their carer; 
monthly meetings for 7 months 
(N = 253) 
Primary end-point
Second follow-up - 10 months after baseline 
Repeat outcome measures completed by person with dementia and their carer 
(N = 400) 
Remote randomisation stratified by whether or not carer is spouse of person with dementia
Baseline data collection - outcome measures completed by person with dementia and their carer
Recruit (N = 576) couples across centresTrials 2009, 10:64 http://www.trialsjournal.com/content/10/1/64
Page 5 of 10
(page number not for citation purposes)
unteers should cover a range of ages and come from the
voluntary sector (e.g. Alzheimer's Society and Age Con-
cern), health professional trainees and former carers with
an understanding of working with older people. The train-
ing programme for facilitators and volunteers is set out in
the RYCT manual, developed during the MRC trial plat-
form [13]. Training engenders skills in listening, interpret-
ing behaviours group dynamics, and enthusing carers and
people with dementia. Two half-day training sessions take
place before each group commences. After each session
there is time for facilitators and volunteers to prepare ses-
sion notes, complete attendance forms and collate evalu-
ation forms. These evaluation forms are collected from
carers and people with dementia at the end of the first ses-
sion and at the end of the 12-week programme. The RYCT
manual recommends a blend of activities for each session,
based on core principles.
The presence of volunteers means that if, for any reason,
carers are not able to attend all the group sessions, the per-
son with dementia can still contribute to the group ses-
sions. Subsequent maintenance sessions are held monthly
and follow a similar pattern – re-visiting some topics and
introducing new topics like a particular decade, for exam-
ple the 1950s with the aid of relevant music and video
clips.
Usual care
The services and interventions available to people with
dementia and family carers randomised to receive usual
treatment will vary between and within centres and over
time. In principle all the interventions offered to this
group will also be available to those in the active treat-
ment groups as we are evaluating the additional effects of
reminiscence work. The only exception to this is when
reminiscence groups occur at the same time as an alterna-
tive intervention. Our commitment to costing services
and interventions received allows us to monitor whether
control groups are receiving alternative interventions in
this way. Though changes and developments in the avail-
ability of medications for Alzheimer's and other demen-
tias should affect both groups equally, we intend to
monitor this through the costing information we collect.
Participants in the usual treatment group may well engage
in some form of reminiscence work during the 10 months
of the study period. This is a popular approach in day-care
centres, and reminiscence materials are widely available.
However it is unlikely that structured reminiscence work
will be offered in any of the centres, and even less likely
that it will be offered jointly to carers. It is this systematic
group-based approach, rather than a general exhortation
to reminisce to improve communication, that is the focus
of this evaluation.
Ethical arrangements
Risks and anticipated benefits for trial participants
There appear to be no documented harmful side-effects
from participating in reminiscence groups and no adverse
reactions were apparent in the MRC trial platform. Some
past memories can be unhappy, and even traumatic, but
with a skilled and trained facilitator participants will share
only those aspects they feel comfortable with, and if dis-
tressing memories were to surface, the person would be
given additional support on a one-to-one basis.
Benefits are consistently reported by participants in the
groups, including enjoyment, feelings of validation and
self-worth. The desire of participants to continue meeting
following the sessions provides an indication of the value
placed on the benefits. Prospective participants will be
fully informed of the potential risks and benefits of the
project.
Nevertheless, a reporting procedure is in place to ensure
that serious adverse events are reported to the Chief Inves-
tigator. Upon becoming aware of an adverse event involv-
ing a participant or carer, a member of the research team
assesses whether it is "serious". A Serious Adverse Event
(SAE) is defined in the trial as an untoward occurrence
experienced by either a participant or carer which:
￿ results in death;
￿ is life threatening;
￿ requires hospitalisation or prolongation of existing
hospitalisation;
￿ results in persistent or significant disability or inca-
pacity;
￿ is otherwise considered medically significant by the
investigator;
￿ falls within the scope of the Protection of Vulnerable
Adults (POVA) protocol which is in place to ensure
that suspected cases of abuse or neglect are followed-
up in an appropriate manner.
A reporting form is submitted to the CI who assesses
whether the SAE is:
￿ related to the conduct of the trial;
￿ unexpected.
SAEs that are judged to be related and unexpected are
reported to MREC and the trial DMEC within 15 days.Trials 2009, 10:64 http://www.trialsjournal.com/content/10/1/64
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Consent
Participants will be in the mild to moderate stages of
dementia, and therefore would generally be expected to
be competent to give informed consent for participation,
provided that appropriate care is taken in explaining the
research and sufficient time is allowed for them to reach a
decision. In every case, the participant will have had at
least 24 hours to consider the information provided. It is
helpful for a family member or other supporter to be
involved, and we would aim to ensure that this is done
wherever possible. Informed consent will be sought sepa-
rately from the family care-giver, in relation to their own
participation. It will be made clear to both participants
and family care-givers that no disadvantage will accrue if
they choose not to participate.
In seeking consent, we will follow current guidance from
the British Psychological Society on evaluation of capac-
ity. In this context, consent has to be regarded as a contin-
uing process rather than a one-off decision, and
willingness to continue participating will be continually
checked through discussion with participants during the
assessments.
Where the participant's level of impairment increases, so
that they are no longer able to provide informed consent,
the provisions of the Mental Capacity Act will be fol-
lowed, with the family care-giver as consultee. Where the
person has themselves given informed consent initially,
this provides a clear indication of the person's likely per-
spective on continuing at later time-points. The same pro-
cedure will apply where the person with dementia appears
to lack capacity to consent initially, but meets the other
criteria for the project. At any point where a participant
with dementia becomes distressed by the assessments
they will be discontinued.
Outcome measures
Primary and secondary measures are completed at base-
line, three months after baseline (first follow-up) and ten
months after baseline (second follow-up and primary
end-point). The interviews for the first follow-up are con-
ducted after the completion of the weekly RYCT sessions,
while the interviews for the second follow-up are sched-
uled after the final monthly maintenance session.
Primary outcome measures
a) Quality of life of the person with dementia, using the
scale Quality of Life in Alzheimer's Disease (QoL-AD) [19],
which covers 13 domains of quality of life. This is reliable
and valid for people with mild and moderate degrees of
dementia when they take part in structured interviews
with trained interviewers [20,21].
b) Care-giver's mental health, assessed using the 28-item,
self-completed General Health Questionnaire GHQ-28 [22]
which has been widely used in care-giver research [23,24];
we shall use four-point Likert scales ranging from zero to
three. The questionnaire includes indicators of anxiety,
depression, insomnia, social dysfunction and somatic
symptoms. We chose the GHQ-28 over the Relatives'
Stress Scale because it is more general and more widely
used.
Secondary outcome measures
a) Autobiographical memory, assessed using an extended
version of the Autobiographical Memory Interview (AMI)
[25]. The extended AMI assesses the person with demen-
tia's recall of personal memories relating to both factual
(semantic) information (for example, names of schools or
teachers) and specific incidents. In the trial platform, we
validated an additional section covering the period from
middle-age to retirement, to cover the life-span of our par-
ticipants.
b) Quality of relationship, assessed by both person with
dementia and carer using the Quality of the Carer-Patient
Relationship  (QCPR) [26]. Originally developed in Bel-
gium this scale comprises 14 items with 5-point Likert
scales designed to assess the warmth of the relationship
and the absence of conflict and criticism. In the trial plat-
form the QCPR had good internal consistency for carers
(α = 0.85) and for people with dementia (α = 0.80), and
concurrent validity with other measures of relationship
quality and carer stress.
c) Depression and anxiety, using Cornell Scale for Depres-
sion in Dementia (CSDD) [27] and Rating Anxiety In
Dementia (RAID) [28] for person with dementia; and Hos-
pital Anxiety and Depression Scale (HADS) [29] for carer.
The CSDD is a 19-item scale, derived from interviews with
the people with dementia and their carers in which the
interviewer describes signs and symptoms to the carer.
Where there is a discrepancy between carer's and clini-
cian's ratings, the interviewer re-interviews the carer
before making a final judgment. The RAID is an 18-item
scale to rate anxiety in people with dementia based on
structured interviews with them and their carers. The
HADS is a well-validated 14-item, self-completed scale
that measures both anxiety and depression, and is suitable
for use with adults of all ages.
d) Stress specific to care-giving, using the Relative's Stress
Scale [30], which asks the care-giver to complete 15 5-
point Likert items.
e) Quality of life of person with dementia, rated by the
care-giver using the proxy version of the QoL-AD [19],Trials 2009, 10:64 http://www.trialsjournal.com/content/10/1/64
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identical in structure and content to the version com-
pleted by the person with dementia.
f) General quality of life of both care-giver and person
with dementia, using EQ-5D [31]. This is a standard meas-
ure of health-related utility, applicable to all health condi-
tions. It provides a simple health profile and a single value
for health status designed to calculate Quality Adjusted
Life Years (QALYs). Care-givers will complete the measure
from their own perspective and for the person with
dementia, who will also complete it whenever possible.
g) Functional ability of person with dementia, using the
Bristol Activities of Daily Living Scale [32], a 20-item scale
completed by the carer.
h) Costs, using the validated Client Services Receipt Inven-
tory (CSRI) [33]. Used extensively in studies of mental
health and dementia (e.g. [34]), this gathers comprehen-
sive data on accommodation, medication and services
received. In this trial the data will reflect either the previ-
ous three months (at baseline and after treatment) or
seven months (at follow-up).
Sample size
Our target sample size is 400 patients completing data col-
lection for the trial after ten months, comprising 200 ran-
domised to attend reminiscence groups and 200 receiving
treatment as usual. In the trial platform intra-class correla-
tion coefficients (ICCs) within randomised groups were
often negative, but never significantly greater than zero,
for both the carer-specific GHQ-28 and the carer-rated
QoL-AD. However they were close to 0.1 for the QoL-AD
rated by the person with dementia. Using a 5% signifi-
cance level, therefore, comparison of the 200 pairs com-
pleting the intervention with the 200 pairs receiving
treatment as usual will yield 80% power of detecting a
standardised difference of 0.28 in carer-specific GHQ-28
or carer-rated QoL-AD. In contrast the patient-rated QoL-
AD is likely to suffer a 'variance inflation factor' of approx-
imately 1.74 [viz. 1 + 0.1 × (average completed group size
of 8.4 minus 1)], thus yielding a power of 80% of detect-
ing a standardised difference of 0.38. Our trial platform,
which had a sample size of 57 in 3 centres, suggests that
standardised differences of 0.28, even 0.38, are plausible.
In our judgement they also fall within the range of clini-
cally important effects. Furthermore, because our trial
platform was exploratory, and therefore more heterogene-
ous than the proposed definitive trial, ICCs and standard
deviations are likely to fall. To achieve a sample size of
approximately 400, we allow for 12% attrition between
recruitment and the post-treatment assessment (estimated
from our trial platform) and a further 18% attrition over
the following 7 months (estimated from a community
study [35]). Hence we seek an initial sample size of 576,
requiring 24 treatment groups initially comprising 12
pairs and another 288 pairs randomised to usual treat-
ment.
Analysis
Statistical Analysis of Effectiveness
We shall analyse by intention to treat and include all
available data. However methods of imputing missing
data such as last observation carried forward (LOCF) are
of limited utility in dementia, where the norm is gradual
decline until loss through death and illness. Hence our
sample size calculations are based on the numbers we
expect to be available at the study end-point, ten months
after randomisation. We shall use multi-level modelling
to address clustering within randomised groups. We shall
use analysis of covariance to adjust for baseline differ-
ences in outcome variables. Analyses will treat ten months
after randomisation as the primary end-point in evaluat-
ing whether the intervention has affected people with
dementia or their care-givers. Secondary analyses will
focus on effects immediately after the intensive group ses-
sions.
Economic Analysis
The principal method will be cost-effectiveness analysis.
We will use established methods for comparing costs and
changes in scores of dementia specific quality of life
instruments between the control and intervention groups
[36]. There is a useful opportunity for secondary cost-util-
ity analysis, more exploratory because estimating the util-
ities of people with dementia is neither easy nor very
precise. To complete the picture, we plan to describe all
costs and effects for people with dementia and their carers
in a cost-consequence analysis.
Cost data
This analysis takes a public sector perspective spanning
the NHS (dementia services, primary and secondary care)
and local government. The interventions received will be
fully costed from the perspective of local dementia serv-
ices to generate a total programme cost and cost per par-
ticipant-carer pair.
The measurement of health service use is the first step in
estimating costs in economic evaluation. We shall esti-
mate the costs of dementia care through the validated
CSRI, completed by the family care-giver. There is a grow-
ing literature to support the reliability of patient recall as
an alternative to GP records [e.g. [37] and our economic
protocol is consistent with that used by previous trials in
this field [33,34]. GP and other provider records are not
an entirely accurate source of service use and hence cost-
ing information. These formal records, though mainly
computer-based, are often incomplete or difficult to link
between primary and secondary NHS care, and social serv-Trials 2009, 10:64 http://www.trialsjournal.com/content/10/1/64
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ices. So collecting data from GPs and other care providers
for the whole sample would add little to the reliability of
use and cost information in the planned evaluation. Nev-
ertheless we propose to compare self-reported visits to pri-
mary and secondary care over the study period by a
sample of 40 participants (20 experimental and 20 con-
trols) with the corresponding GP notes to estimate sys-
tematic differences in reports. As the difference in costs
and effects between groups is of primary interest, it is
especially important to treat these groups identically
when costing.
We shall use national unit costs [38,39] to convert service
use to monetary costs, including:
￿ costs of running the joint reminiscence groups;
￿ costs of reminiscence-based maintenance groups fol-
lowing the initial intervention;
￿ direct costs of all health care used by participants in
the intervention and control arms of the study, includ-
ing contacts with GPs and practice nurses at home, in
surgery or by phone, prescribing and outpatient and
inpatient attendances); and
￿ indirect costs of lost productivity and care-givers
attending group sessions;
but not intangible costs.
Effectiveness data
We shall evaluate effectiveness through the primary clini-
cal outcomes – QoL-AD, the dementia-specific measure of
quality of life and the carer-specific GHQ-28 – both at the
primary end-point of 10 months.
Incremental Cost-effectiveness Analysis
Incremental cost-effectiveness ratios (ICERs) will summa-
rise changes in the costs and effects of improving quality
of life of people with dementia and stress in their care-giv-
ers through joint reminiscence group therapy followed by
reminiscence-based maintenance, compared with usual
care. We shall use bootstrapping to characterise the uncer-
tainty in the cost-effectiveness analysis by estimating the
probability distribution of ICERs and generating cost-
effectiveness acceptability curves (CEACs) to quantify and
display that uncertainty. Though CEACs are widely used
in economic evaluation of health care technologies [40],
they are no less useful in the evaluation of psycho-social
interventions.
Sensitivity analysis
We shall use sensitivity analyses to assess whether
assumptions underpinning economic analyses affect the
results of those analyses. For example, we shall assess how
collecting data for only 10 months and assuming no dif-
ferential effects beyond that point, affects ICERs and
CEACs relative to assumptions like differences at 10
months decline to zero over next 10 months.
Secondary Cost-Utility Analysis
We shall conduct an exploratory cost-utility analysis using
EQ-5D to calculate QALYs for carers and people with
dementia, if necessary by getting carers to complete the
EQ-5D 'by proxy' for people with dementia [41,42]. The
addition of EQ-5D to interview schedules for both care-
givers and people with dementia will enable us to esti-
mate and potentially combine the health utility gains to
both people with dementia and their carers. This responds
to the recommendations from NICE to include utility
measures in trials of new drugs and interventions to facil-
itate cost per QALY calculation and consider the health
effects of an intervention regardless of who receives them:
"For the reference case, the perspective on outcomes
should be all direct health effects whether for patients or,
where relevant, other individuals (principally carers)"
[43]. Dixon et al have recently highlighted the potential
influence on cost per QALY ratios of adding the health
utility gains of carers to those of people with conditions
like dementia [42]. Given the findings of the trial plat-
form, we predict that both the costs and effects of reminis-
cence therapy may be modest, with the result that the cost
per QALY ratio may have a large standard error. Added to
our concern about using a generic measure of quality of
life for people with dementia, this leads us to label the
cost-utility analysis as secondary to the cost effectiveness
analysis.
Cost-Consequence Analysis
Cost-consequence analysis estimates the incremental
costs and consequences of alternative programmes with-
out aggregation. In particular our analysis will compare
secondary outcomes of experimental and control partici-
pants at baseline, 3 months, and 10 months, thus elabo-
rating on the summative cost effectiveness and cost utility
analyses by addressing a wider range of costs and conse-
quences arising from reminiscence therapy. This will help
commissioners and policy-makers responsible for fund-
ing and coordinating services.
Discussion
This paper summarises the study protocol of an innova-
tive and pragmatic RCT that evaluates the effectiveness
and cost-effectiveness of joint reminiscence groups and
maintenance sessions for people with dementia and their
carers. Our Cochrane review [12] generated this, the first
rigorous trial of joint reminiscence groups and one of the
first integrated cost-effectiveness studies of a psycho-social
intervention for dementia. With its emphasis on workingTrials 2009, 10:64 http://www.trialsjournal.com/content/10/1/64
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with the person with dementia and family carer together,
our therapeutic approach reflects current emphasis on
'relationship-centred care', and our trial will accurately
estimate the outcomes for both parties. The NICE-SCIE
guidelines on the management of dementia offered few
evidence-based recommendations on psychosocial
approaches because there were few good studies. The
results of this trial will contribute to future updates of
these guidelines, so that the approach becomes widely
used in health and social care, if successful in this trial.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
Contributions: RTW, MO & EB developed the original
concept for the trial, and RTW drafted the original proto-
col; ITR developed the design and methodology; RTE
developed the health economic component; EB co-
authored the treatment manual; BH & RTE adapted the
trial proposal as a protocol paper; all authors reviewed
and commented on drafts of the protocol and paper.
Appendix
Inclusion and exclusion criteria
Inclusion criteria
All participants are people with dementia who:
•  meet the DSM-IV criteria for dementia of any type,
including Alzheimer's, vascular, Lewy Body type and
mixed;
•  are in the mild to moderate stage of dementia (Clin-
ical Dementia Rating);
•  can communicate and understand communication,
shown by a score of 1 or 0 on the relevant items of the
Clifton Assessment Procedures for the Elderly – Behav-
iour Rating Scale;
•  can engage in group activity;
•  live in the community at the time of the baseline
assessment and have a relative or other care-giver who
maintains regular contact, can act as informant, and is
willing and able to participate in the intervention with
the person with dementia.
Exclusion criteria
Participants do not have any characteristic which could
affect participation, e.g.:
•  major physical illness;
•  sensory impairment;
•  disability; or
•  high level of agitation.
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